Breast cancer patients who had an ER and PR positive status showed 14.05- (p=0.03) and 15.29-fold (p=0.005) NRXN-1 mRNA expression while ER and PR negative patients showed 10.52- and 10.18-fold NRXN-1 mRNA expression, respectively. This evidence concerns the gene NRXN1 and breast cancer.